S.Biomedics Co., Ltd. (KOSDAQ:304360)
30,650
-1,650 (-5.11%)
At close: Feb 6, 2026
S.Biomedics Revenue
S.Biomedics had revenue of 3.25B KRW in the quarter ending September 30, 2025, a decrease of -3.93%. This brings the company's revenue in the last twelve months to 16.96B, up 30.26% year-over-year. In the year 2024, S.Biomedics had annual revenue of 13.73B with 4.77% growth.
Revenue (ttm)
16.96B
Revenue Growth
+30.26%
P/S Ratio
22.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
379.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13.73B | 625.65M | 4.77% |
| Dec 31, 2023 | 13.11B | 995.73M | 8.22% |
| Dec 31, 2022 | 12.11B | 3.24B | 36.58% |
| Dec 31, 2021 | 8.87B | 3.55B | 66.72% |
| Dec 31, 2020 | 5.32B | 305.34M | 6.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Cell | 170.13B |
| HansBiomed | 89.78B |
| ISU Abxis | 66.39B |
| NIBEC | 32.96B |
| Genome & Company | 25.95B |
| Prestige Biologics | 13.36B |
| Y-Biologics | 3.61B |
| Vaxcell-Bio Therapeutics | 1.90B |